Wanbury Limited
Regd. Office: BSEL Tech Park, B-Wing, 10th Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA
Tel: +91-22-6794 2222
+91-22-7196 3222
CIN: L51900MH1988PLC048455
Email: info@wanbury.com
Website: www.wanbury.com

November 20, 2026

BSE Limited PJ. Towers, Dalal Street Mumbai – 400 001. Scrip Code: **524212**	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400 051. SYMBOL: **WANBURY**

Dear Sir/Madam,

Subject: Wanbury Limited's Tanuku API Facility Successfully Completes South Korea MFDS cGMP Inspection with Zero Observations

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Wanbury Limited's API manufacturing facility at Tanuku, Andhra Pradesh, has successfully completed a three-day cGMP inspection conducted by the Ministry of Food and Drug Safety (MFDS), Republic of Korea, with zero observations.

The inspection was conducted by two senior inspectors from South Korea's MFDS, a leading international pharmaceutical regulatory authority, covering the facility's compliance with applicable Good Manufacturing Practices (cGMP) standards.

This achievement follows the successful completion of a South Korea MFDS cGMP inspection at the Company's Patalganga manufacturing facility in April 2026, which was also concluded with zero observations.

These consecutive achievements reflect Wanbury Limited's strong commitment to quality, regulatory compliance and operational excellence. The Company remains focused on continuously strengthening its quality systems and enhancing manufacturing standards in line with evolving international regulatory requirements and global cGMP expectations.

We request you to take the above on record.

Thanking you.

Yours faithfully,
For Wanbury Limited

JITENDRA JAYANTILAL GANDHI
Digitally signed by JITENDRA JAYANTILAL GANDHI
Date: 2026.11.20 00:58:32 +05'30'

Jitendra J. Gandhi
Company Secretary

US Europe Brazil Korea India Mexico Canada China WHO GMP